Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Decrease in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 26,405 shares, a drop of 86.1% from the May 14th total of 189,821 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 341,001 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Trading Down 0.6%

Shares of ALPMY opened at $13.21 on Thursday. Astellas Pharma has a 1-year low of $9.11 and a 1-year high of $17.35. The company has a 50-day moving average of $14.93 and a 200 day moving average of $14.60. The firm has a market capitalization of $23.91 billion, a price-to-earnings ratio of 12.30 and a beta of 0.07. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.28 billion. On average, research analysts expect that Astellas Pharma will post 1.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a report on Monday, February 16th. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Finally, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, May 25th. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Astellas Pharma presently has an average rating of “Hold”.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).